Francisco Partners Iv, L.P. Sells 127,273 Shares of GoodRx (NASDAQ:GDRX) Stock

Posted by Brenda Bartman on Aug 28th, 2026

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $3.44, for a total value of $437,819.12. Following the completion of the transaction, the insider directly owned 643,466 shares in the company, valued at $2,213,523.04. This represents a 16.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50.
On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The stock was sold at an average price of $3.46, for a total value of $496,835.24.
On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68.
On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Trading Down 3.8%

Shares of NASDAQ GDRX opened at $3.51 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx Holdings, Inc. has a 12 month low of $1.77 and a 12 month high of $5.81. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 87.77, a P/E/G ratio of 1.82 and a beta of 1.60. The business has a fifty day simple moving average of $3.19 and a 200-day simple moving average of $2.67.

GoodRx (NASDAQ:GDRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.GoodRx’s revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the business posted $0.09 EPS. Sell-side analysts predict that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. Technology Crossover Management X Ltd. acquired a new position in GoodRx in the 2nd quarter valued at approximately $4,762,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of GoodRx during the 4th quarter valued at $1,585,000. LSV Asset Management boosted its stake in shares of GoodRx by 20.0% during the 4th quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock valued at $7,658,000 after buying an additional 471,319 shares during the period. Prescott Group Capital Management L.L.C. purchased a new position in shares of GoodRx during the 4th quarter valued at $4,812,000. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of GoodRx by 10,242.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock valued at $4,072,000 after acquiring an additional 1,488,137 shares in the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Citigroup raised their price objective on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. UBS Group lifted their price objective on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Barclays boosted their target price on shares of GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research note on Thursday, August 20th. Finally, Wells Fargo & Company increased their target price on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, GoodRx presently has a consensus rating of “Hold” and an average target price of $4.23.

Read Our Latest Stock Report on GDRX

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.